AR splice variants lacking the LBD but retaining the N-terminal domain (NTD) and DNA-binding domain (DBD) remain constitutively active in the absence of androgen binding, thereby activating downstream signaling pathways and driving prostate cancer resistance and progression (Fig. 2C) [9]. This evidence concerns the gene AR and prostate carcinoma.